STX12 and metabolic disease: CDN1163, a small molecule activator of SERCA, has shown promise in modulating cellular functions related to diabetes and metabolic disorders.[46] Here, CDN1163 treatment significantly increased EF% and FS% in both Stx12‐cKO mice and wild‐type mice (Figure S8, Supporting Information), demonstrating the therapeutic potential of targeting SERCA activity to ameliorate cardiac dysfunction.